Back

Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

1 September 2019 (14:30 - 14:45)
Organised by:
Congress Presentation Part of: Young Investigator Award Session Thrombosis Secondary Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Miss Tamar de Vries

University Medical Center Utrecht, Utrecht (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
The prothrombotic transcriptome of reticulated platelets
Doctor D. Bongiovanni (Augsburg, DE)
Abstract Slides Video
Presentation thumbnail
Sirtuin 5 regulates arterial thrombosis by modulating endothelial plasminogen activator inhibitor-1
Doctor L. Liberale (Genova, IT)
Abstract Slides Video
Presentation thumbnail
Intravenous administration of IV-STATIN CARDIOSHIELD during myocardial infarction renders higher cardioprotection than oral atorvastatin given shortly after reperfusion: a translational CMR study
Doctor G. Mendieta Badimon (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award Session Thrombosis

The Event

Event poster

ESC Congress 2019

1 September 2019 14:30 CET
You may be interested in
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources